PKM and myeloid sarcoma: However, no study analysed in detail the expression of PKM2 in human T cell subsets, and whether targeting PKM2 may limit the inflammatory potential of T cells from patients with MS is unknown.<h4>Methods</h4>In this observational, case control study we evaluated the expression of PKM2 in circulating T cells of healthy control individuals (HCs) and patients with MS, as well as its isomerisation in peripheral blood mononuclear cells (PBMCs) from HCs and patients.